ARCHIVES

FDA Backs Down, Releases INDs, But Revives Controversy Over Clinical Testing Guidelines

This article is from The Cancer Letter archive.

Vol. 02 No. 11 | March 12, 1976

Download PDF Visit The Full Archive

Related Articles

Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.

February 15, 2002

mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients

February 25, 2011

Cancer Panel To Examine Health Of Phase I Trials

May 17, 1996

FDA Didn’t Punish Duke for Failing To Seek Proper Regulatory Clearance for Three Trials

January 27, 2012

“Sloppy” Cancer Control Grant Applications Turned Down At Twice NIH Disapproval Rate

November 7, 1975

NCCN Also to Warn Doctors. Amgen’s Pledges to Disclose Future Results.

February 23, 2007